🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Weekend_review on #menin_inhibitors for treatment of leukemia in light on Revumenib approval (AUGMENT-101) #leusm #AML 🧵 FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation fda.gov/drugs/resource…

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations ashpublications.org/blood/article/…

Really happy to have presented ASH 2024 two oral presentations on behalf of the GETH and CETLAM about the AlloHCT Refined ELN 2022 Risk Classification validation and the prognostic value of MRD in AML patients treated with VenHMA Hematologia Hospital Clínic Barcelona

Carlos Jimenez Carlos Jiménez-Vicente from Hematologia Hospital Clínic Barcelona presented at #ASH2024 a collaborative study by CETLAM highlighting the prognostic role of MRD assessment in AML patients treated with VEN+HMA

🚨 REUNIÓN CETLAM 🚨 El 20 de diciembre celebraremos la Reunión de Investigación 2024 en la Casa de Convalecencia del Recinte Modernista de Sant Pau. También disponible vía Zoom. Inscripciones 👉 tinyurl.com/yvfrnn6e

Thrilled to share our latest study: “At-Home (AH) care program for Acute Myeloid Leukemia (AML) patients undergoing induction therapy with Venetoclax + Azacitidine (VenAza) 🧵 mdpi.com/3100452 #mdpicancers via Cancers MDPI

📝 A retrospective analysis of CETLAM and PETHEMA registries, published in Cancers MDPI, confirms the real-world effectiveness and tolerability of gilteritinib and quizartinib monotherapy in patients with FLT3-mutated R/R AML. More news: aml-hub.com #AMLsm #MedEd

🔊 Excited to share the #Article "Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups" 📌 Access the full paper here: mdpi.com/2072-6694/16/2… 👏 by Susana Vives et al. Universitat Autònoma de Barcelona

💡Check our new paper by H. Castellet et al describing the CETLAM series of UBTF-TD in adult AML and proposing new methods for MRD assessment in this rare subtype of AML: onlinelibrary.wiley.com/doi/full/10.11…

It was a real pleasure to present our experience with the AH follow-up of aplasia after HD chemotherapy in AML patients at WHAHC Thanks to my co-presenters and attendees for the engaging conversations! 🙌 Hospital Clínic #WHAHC2025

Happy to share the latest AML manuscript within HARMONY: "Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance" recently published in Haematologica: haematologica.org/haematologica/… HARMONY Alliance Foundation #AMLsm

👉REUNIÓN ANUAL CETLAM 2025 Tendrá lugar los días 29 y 30 de mayo en la Casa de Convalescència en Barcelona. Ya disponible el programa científico de la sesión educacional. Inscripciones vía: [email protected]

Our 6-center Spanish CETLAM study of 99 AML pts on VenHMA achieving a morphological response is out in Blood Cancer Journal. Achieving MRD– improved OS (23.3 vs 15.2m, p=0.006) and LFS being the only independent factor in MVA. Thanks to all authors! nature.com/articles/s4140…

💫 New in Blood Cancer Journal MRD predicts OS and LFS in AML patients treated with HMA-VEN. Study by Carlos Jiménez-Vicente featuring data from 6 CETLAM centers. nature.com/articles/s4140…

Empieza!!😊Reunión anual del CETLAM #LMA

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia | haematologica.org/article/view/1…